At ASH 2022, an update on efficacy and safety among 57 patients with r/r CLL (≥ 2 prior therapies, including patients with a BTK C481 mutation or intolerant to covalent BTKI) treated with nemtabrutinib at a target dose of 65 mg was presented. Here, BTK is linked to B-cell chronic lymphocytic leukemia.